JP2008516614A - リステリア増殖のための高細胞密度法 - Google Patents

リステリア増殖のための高細胞密度法 Download PDF

Info

Publication number
JP2008516614A
JP2008516614A JP2007537041A JP2007537041A JP2008516614A JP 2008516614 A JP2008516614 A JP 2008516614A JP 2007537041 A JP2007537041 A JP 2007537041A JP 2007537041 A JP2007537041 A JP 2007537041A JP 2008516614 A JP2008516614 A JP 2008516614A
Authority
JP
Japan
Prior art keywords
listeria
culture
medium
protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007537041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008516614A5 (cg-RX-API-DMAC7.html
Inventor
スウェエネイ パメラ
エー. ルッセルル ブリアン
Original Assignee
メディミューン,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディミューン,インコーポレーテッド filed Critical メディミューン,インコーポレーテッド
Publication of JP2008516614A publication Critical patent/JP2008516614A/ja
Publication of JP2008516614A5 publication Critical patent/JP2008516614A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2007537041A 2004-10-18 2005-10-18 リステリア増殖のための高細胞密度法 Abandoned JP2008516614A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62013304P 2004-10-18 2004-10-18
PCT/US2005/038237 WO2006045110A2 (en) 2004-10-18 2005-10-18 High cell density process for growth of listeria

Publications (2)

Publication Number Publication Date
JP2008516614A true JP2008516614A (ja) 2008-05-22
JP2008516614A5 JP2008516614A5 (cg-RX-API-DMAC7.html) 2008-12-04

Family

ID=36203744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007537041A Abandoned JP2008516614A (ja) 2004-10-18 2005-10-18 リステリア増殖のための高細胞密度法

Country Status (6)

Country Link
US (1) US20060121053A1 (cg-RX-API-DMAC7.html)
EP (1) EP1802338A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008516614A (cg-RX-API-DMAC7.html)
AU (1) AU2005295158A1 (cg-RX-API-DMAC7.html)
CA (1) CA2584130A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006045110A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513502A (ja) * 2014-04-24 2017-06-01 アドバクシス, インコーポレイテッド 組み換え型リステリアワクチン株およびこれを生産する方法

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US7662396B2 (en) * 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8791237B2 (en) * 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US6051237A (en) * 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
JP2004500405A (ja) * 2000-03-29 2004-01-08 ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルヴァニア 抗原の免疫原性を増強するための組成物および方法
US7700344B2 (en) * 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
WO2007061848A2 (en) * 2005-11-17 2007-05-31 The Trustees Of The University Of Pennsylvania Methods for producing, growing, and preserving listeria vaccine vectors
EP2056849A4 (en) * 2006-08-04 2010-09-08 Univ Pennsylvania METHOD AND COMPOSITIONS FOR TREATING IGE-MEDIATED ILLNESSES
US8241636B2 (en) * 2006-08-15 2012-08-14 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
US8268326B2 (en) * 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
JP5757863B2 (ja) 2008-05-19 2015-08-05 アドバクシス インコーポレイテッド 異種抗原のための二重送達システム
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US8778329B2 (en) 2009-03-04 2014-07-15 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
CN107412756A (zh) 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria
EP3313975A4 (en) * 2015-06-24 2019-03-13 Advaxis, Inc. MANUFACTURING DEVICE AND METHOD FOR PERSONALIZED ADMINISTRATION OF VECTOR-BASED IMMUNOTHERAPY
US10774390B2 (en) * 2015-09-02 2020-09-15 The Regents Of The University Of California Methods and compositions for modulating PrfA mediated virulence gene activation in Listeria spp
US20180325964A1 (en) * 2015-11-20 2018-11-15 Advaxis, Inc. Manufacturing device and method of an immunotherapeutic formulation comprising a recombinant listeria strain
JP7284156B2 (ja) * 2017-09-19 2023-05-30 アドバクシス, インコーポレイテッド 細菌またはListeria株の凍結乾燥のための組成物および方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6051237A (en) * 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7425449B2 (en) * 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
EP1519956B1 (en) * 2002-05-10 2011-09-21 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
JP2006507256A (ja) * 2002-09-24 2006-03-02 ザ バーナム インスティチュート Eph受容体活性を調節する新規薬剤
ATE552843T1 (de) * 2003-02-06 2012-04-15 Aduro Biotech Listerien deren eindringen in nicht-phagozytische zellen abgeschwächt ist, impfstoffe, die diese listerien enthalten und deren verwendungen
EP1618184A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc EPHA2, HYPOPROLIFERATIVE CELL DISORDERS, AND EPITHELIAL AND ENDOTHELIAL RECONSTITUTION
EP1617864A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc EPHA2 AND NON-NEOPLASTIC HYPERPROLIFERATIVE CELL TROUBLESHOOTING
US20050147593A1 (en) * 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
CA2533789C (en) * 2003-07-30 2013-09-17 University Of Pittsburgh Of The Commnonwealth System Of Higher Education Epha2 t-cell epitope agonists and uses therefor
EP1660186B1 (en) * 2003-08-18 2013-12-25 MedImmune, LLC Humanization of antibodies
US20050042664A1 (en) * 2003-08-22 2005-02-24 Medimmune, Inc. Humanization of antibodies
KR20060130038A (ko) * 2003-10-15 2006-12-18 메디뮨 인코포레이티드 리스테리아에 의거한 EphA2 백신
US20050153923A1 (en) * 2003-12-04 2005-07-14 Kinch Michael S. Targeted drug delivery using EphA2 or EphA4 binding moieties
EP1773391A4 (en) * 2004-06-25 2009-01-21 Medimmune Inc INCREASING THE PRODUCTION OF RECOMBINANT ANTIBODIES IN MAMMALIAN CELLS BY MUTAGENESIS ON THE SITE
AU2005277641A1 (en) * 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
EP1812077A4 (en) * 2004-10-27 2009-12-02 Medimmune Inc MODULATORS OF EPHA2 AND EPHRINA1 FOR TREATING A FIBROSIS-ASSOCIATED DISEASE
WO2006047639A2 (en) * 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20060121043A1 (en) * 2004-10-27 2006-06-08 Medimmune, Inc. Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections
EP1809583A2 (en) * 2004-11-01 2007-07-25 MedImmune, Inc. Ultra high throughput capture lift screening methods
WO2006081418A2 (en) * 2005-01-27 2006-08-03 The Burnham Institute Ephb receptor-binding peptides
US20050181479A1 (en) * 2005-03-04 2005-08-18 Medimmune, Inc. Periplasmic expression of antibodies using a single signal sequence
AU2006304387A1 (en) * 2005-10-14 2007-04-26 Medimmune, Llc Cell display of antibody libraries

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513502A (ja) * 2014-04-24 2017-06-01 アドバクシス, インコーポレイテッド 組み換え型リステリアワクチン株およびこれを生産する方法

Also Published As

Publication number Publication date
US20060121053A1 (en) 2006-06-08
WO2006045110A2 (en) 2006-04-27
EP1802338A4 (en) 2010-01-27
EP1802338A2 (en) 2007-07-04
WO2006045110A3 (en) 2009-04-09
AU2005295158A1 (en) 2006-04-27
CA2584130A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
US20060121053A1 (en) High cell density process for growth of Listeria
EP2461833B1 (en) Vaccine composition comprising 5'-cap modified rna
KR102049928B1 (ko) 효모-muc1 면역요법 조성물 및 그 용도
JP5530065B2 (ja) 抗生物質耐性欠失ワクチンの作成方法
JP2021525079A (ja) 水痘・帯状疱疹ウイルスの抗原バリアントおよびその使用
RU2653757C2 (ru) Модифицированные грамположительные бактерии и их применение
JP2010508861A (ja) 抗原およびタンパク質毒素をコードする異種ヌクレオチド配列からなる担体としての微生物、その生成方法、ならびにその使用
KR20060130038A (ko) 리스테리아에 의거한 EphA2 백신
US7883696B2 (en) Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type I interferon response
CN104838004A (zh) 兼性减毒细菌种类及其制备和使用方法
JP2015511602A (ja) リステリアワクチン処理後のサプレッサー細胞機能抑制
US20210085771A1 (en) Method for inducing a tolerogenic immune response
US20250213673A1 (en) Compositions and methods
US20150175996A1 (en) Dna composition for eliciting an immune response against tumor-associated macrophages
JP2019526262A5 (cg-RX-API-DMAC7.html)
US20150132325A1 (en) Novel compositions and uses therefor
TW202328429A (zh) 一種經遺傳修飾的微生物及其應用
WO2003029289A2 (en) Fragements of heat shock proteins and their use
CN103695327B (zh) 一种口服重组酵母及其介导的靶向肠道DC呈递shRNA的应用
Vos et al. Phenotypic and functional characterization of a panel of cytotoxic murine NK cell clones that are heterogeneous in their enhancement of Ig secretion in vitro.
CN110603053A (zh) 重组衣原体活化的b细胞平台及其使用方法
JP6802924B2 (ja) シスタチンを発現及び分泌する胃腸管疾患治療薬物伝達用ペジオコックスペントサセウス菌株及びそれを含む胃腸管疾患予防又は治療用薬剤学的組成物
Didenko et al. Efficiency of xenogeneic antitumor vaccine in vivo
KR101045670B1 (ko) 돼지 인터류킨-18 유전자를 발현하는 살모넬라 균주 및 이를 함유하는 경구 투여용 조성물
RU2546917C1 (ru) Способ микробиологического синтеза гибридного белка е7-hsp70 (варианты)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081016

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20101118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101118